Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era.

IF 1 Q4 ONCOLOGY

Current Breast Cancer Reports Pub Date : 2022-01-01 Epub Date: 2022-12-06 DOI:10.1007/s12609-022-00469-9

Genevieve A Fasano, Solange Bayard, Tamika Gillot, Zuri Hannibal, Marian Pedreira, Lisa Newman

{"title":"Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era.","authors":"Genevieve A Fasano, Solange Bayard, Tamika Gillot, Zuri Hannibal, Marian Pedreira, Lisa Newman","doi":"10.1007/s12609-022-00469-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers.Recent findings: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown.Summary: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary.","PeriodicalId":10769,"journal":{"name":"Current Breast Cancer Reports","volume":"14 4","pages":"213-221"},"PeriodicalIF":1.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735127/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Breast Cancer Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12609-022-00469-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers.

Recent findings: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown.

Summary: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary.

Abstract Image

查看原文本刊更多论文

乳腺癌治疗时间的差异：COVID-19 时代的现有知识和未来方向》。

审查目的：尽管在乳腺癌的检测和治疗方面取得了重大进展，但黑人妇女的乳腺癌死亡率仍比白人妇女高出 40%。及时的检查和治疗可改善预后，但目前尚无黄金标准来指导医疗服务提供者：大量文献表明，在乳腺癌治疗时间上存在差异，大多数研究显示，黑人妇女接受治疗的时间晚于白人妇女。总结：在这篇综述中，我们描述了有关治疗时间差异、潜在驱动因素和可能的缓解策略的现有证据。未来的研究必须探讨 COVID-19 大流行如何影响乳腺癌患者的及时治疗，尤其是易受差异结果影响的人群。有必要改善多学科乳腺项目、患者导航服务的获取途径，并制定及时治疗的标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Breast Cancer Reports ONCOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of breast cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as prevention, systemic therapy, and translational research. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.